Business Context and Reporting Period
This Form 8-K, filed on April 25, 2022, by Crane Co. (NYSE: CR), reports the results of operations for the quarter ended March 31, 2022. The filing primarily details the Company's ongoing exposure to asbestos-related litigation, including claim activity, costs incurred, and liability estimates.
Key Financial Metrics: Asbestos Litigation
The filing provides specific financial data regarding asbestos claims and costs for the three months ended March 31, 2022, compared to the prior year period.
| Metric (in millions) | Q1 2022 | Q1 2021 |
|---|---|---|
| Total Costs Incurred (Settlement & Defense) | $13.0 | $9.1 |
| Settlement/Indemnity Costs Incurred | $10.5 | $5.5 |
| Defense Costs Incurred | $2.5 | $3.6 |
| Pre-tax Cash Payments (Net of Insurance) | $7.5 | $10.8 |
| Insurance Receipts | $4.2 | $2.5 |
Liability and Asset Balances:
- Total Asbestos Liability: $600 million as of March 31, 2022 (down from $612 million at December 31, 2021).
- Current Portion of Liability: $62.3 million (estimated costs payable within 12 months).
- Insurance Receivable Asset: $70 million as of March 31, 2022 (down from $74 million at December 31, 2021).
Claim Activity:
- 30,312 as of March 31, 2022 (up from 29,958 at December 31, 2021).
- 657.
- Resolved Claims (Cumulative): Approximately 144,000 claims resolved through March 31, 2022.
Material Changes and Trends
Costs incurred for asbestos settlements and defense increased by approximately 43% in the first quarter of 2022 compared to the same period in 2021 ($13.0 million vs. $9.1 million). This increase was driven primarily by higher settlement/indemnity costs ($10.5 million vs. $5.5 million). Conversely, net cash payments decreased to $7.5 million from $10.8 million in the prior year, reflecting a lag between cost recognition and cash settlement, as well as increased insurance receipts.
The total recorded liability decreased slightly by $12 million during the quarter, while the number of pending claims increased by 354. Approximately 18,000 of the pending claims are in New York, with roughly 16,000 being inactive non-malignancy claims filed over 15 years ago.
Outlook, Risks, and Management Commentary
Liability Estimate Methodology: Management utilizes an independent actuarial firm to estimate liabilities through 2059. The estimate is based on historical claim experience, epidemiological studies, and defense cost forecasts. Key variables include the number of new mesothelioma claims, average settlement costs, dismissal rates, and defense costs.
Management Determination: Based on the review of claims experience and qualitative factors (including appellate rulings and legislative developments), management determined that no change to the liability estimate was warranted for the period ended March 31, 2022.
Insurance Coverage: The Company has settled with all but two of its solvent excess insurers. The model forecasts that approximately 14% of the total liability will be reimbursed by insurers. The Company notes that actual reimbursements vary and will decline over time.
Risks and Uncertainties: The filing highlights significant uncertainties regarding the ultimate exposure. Factors that could materially alter the liability estimate include:
- Significant trends in the number or severity of claims filed.
- Adverse verdicts at trial that withstand appeal.
- Changes in case law, court procedures, or federal legislation.
- Financial viability of insurance carriers.
The filing explicitly states that the filing text does not provide specific revenue, profit, or general cash flow metrics for the quarter; these are contained in the referenced Exhibit 99.1 (Earnings Press Release).
Investor Verification Checklist
- Exhibit 99.1 Review: Verify the full Q1 2022 revenue, net income, and operating cash flow figures in the attached Earnings Press Release, as they are not detailed in this 8-K text.
- Liability Sensitivity: Assess the impact of the $600 million asbestos liability on the Company's balance sheet and future cash flow projections, noting the $62.3 million current portion.
- Insurance Recovery Risk: Evaluate the $70 million insurance receivable asset against the financial stability of the remaining excess insurers and the 14% estimated recovery rate.
- Claim Trends: Monitor the ratio of new claims (657 in Q1) versus dismissals (102 in Q1) to gauge the trajectory of the 30,312 pending claims.
- Legal Precedents: Review recent appellate rulings in New York and other key jurisdictions that could alter the "Dummitt" decision framework or settlement values.